- Home
- RLTY vs RIGL Comparison
RLTY vs RIGL Comparison
Compare RLTY & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RLTY
- RIGL
- Stock Information
- Founded
- RLTY 2022
- RIGL 1996
- Country
- RLTY United States
- RIGL United States
- Employees
- RLTY N/A
- RIGL N/A
- Industry
- RLTY Investment Managers
- RIGL Biotechnology: Pharmaceutical Preparations
- Sector
- RLTY Finance
- RIGL Health Care
- Exchange
- RLTY Nasdaq
- RIGL Nasdaq
- Market Cap
- RLTY 256.9M
- RIGL 486.4M
- IPO Year
- RLTY N/A
- RIGL 2000
- Fundamental
- Price
- RLTY $14.82
- RIGL $17.09
- Analyst Decision
- RLTY
- RIGL Buy
- Analyst Count
- RLTY 0
- RIGL 5
- Target Price
- RLTY N/A
- RIGL $34.80
- AVG Volume (30 Days)
- RLTY 86.7K
- RIGL 189.6K
- Earning Date
- RLTY 01-01-0001
- RIGL 11-07-2024
- Dividend Yield
- RLTY 9.35%
- RIGL N/A
- EPS Growth
- RLTY N/A
- RIGL N/A
- EPS
- RLTY N/A
- RIGL 0.22
- Revenue
- RLTY N/A
- RIGL $157,374,000.00
- Revenue This Year
- RLTY N/A
- RIGL $48.98
- Revenue Next Year
- RLTY N/A
- RIGL $14.43
- P/E Ratio
- RLTY N/A
- RIGL $76.64
- Revenue Growth
- RLTY N/A
- RIGL 21.65
- 52 Week Low
- RLTY $11.38
- RIGL $7.48
- 52 Week High
- RLTY $14.60
- RIGL $29.82
- Technical
- Relative Strength Index (RSI)
- RLTY 22.43
- RIGL 30.82
- Support Level
- RLTY $14.56
- RIGL $16.68
- Resistance Level
- RLTY $16.00
- RIGL $19.80
- Average True Range (ATR)
- RLTY 0.26
- RIGL 1.53
- MACD
- RLTY -0.14
- RIGL -1.05
- Stochastic Oscillator
- RLTY 2.44
- RIGL 3.66
About RLTY Cohen & Steers Real Estate Opportunities and Income Fund of Beneficial Interest
Cohen & Steers Real Estate Opportunities and Income Fund is an organized, non-diversified, closed-end management investment company. The Fund's primary investment objective is high current income. The Fund's secondary investment objective is capital appreciation.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.